Key Points
- Director purchase: Amy Mcbride Wendell bought 1,475 shares at an average price of $68.03 for $100,344.25, increasing her stake by 41.39% to 5,039 shares valued at $342,803.17.
- $1.00 billion repurchase program: Solventum's board authorized up to $1.0 billion in buybacks (about 7.5% of shares), a move management says reflects confidence the stock is undervalued.
- Quarterly beat and guidance: Solventum reported $1.57 EPS vs. $1.50 expected on $2.0B revenue and set FY2026 guidance of $6.40–$6.60 EPS (analysts expect ~6.58).
Solventum Corporation (NYSE:SOLV - Get Free Report) Director Amy Mcbride Wendell purchased 1,475 shares of the company's stock in a transaction on Tuesday, March 10th. The shares were bought at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares in the company, valued at $342,803.17. This represents a 41.39% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Solventum Price Performance
Shares of NYSE SOLV traded down $0.34 during trading on Thursday, hitting $67.28. The company had a trading volume of 133,687 shares, compared to its average volume of 1,093,972. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $88.20. The business's 50-day moving average is $76.91 and its 200 day moving average is $76.08. The company has a market cap of $11.67 billion, a P/E ratio of 7.58, a PEG ratio of 1.11 and a beta of 0.40. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23.
Solventum (NYSE:SOLV - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.96 billion. During the same period last year, the firm posted $1.41 earnings per share. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Equities research analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.
Solventum announced that its Board of Directors has initiated a stock repurchase program on Thursday, November 20th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to purchase up to 7.5% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its shares are undervalued.
Institutional Investors Weigh In On Solventum
Institutional investors and hedge funds have recently made changes to their positions in the company. United Services Automobile Association bought a new stake in shares of Solventum during the first quarter worth $239,000. Woodline Partners LP boosted its holdings in Solventum by 40.7% during the first quarter. Woodline Partners LP now owns 11,677 shares of the company's stock worth $888,000 after purchasing an additional 3,377 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of Solventum by 167.0% in the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company's stock valued at $1,268,000 after buying an additional 10,425 shares in the last quarter. Resona Asset Management Co. Ltd. boosted its position in Solventum by 2.0% during the second quarter. Resona Asset Management Co. Ltd. now owns 49,786 shares of the company's stock worth $3,773,000 after purchasing an additional 971 shares during the period. Finally, Aviva PLC boosted its stake in Solventum by 6.8% in the 2nd quarter. Aviva PLC now owns 103,452 shares of the company's stock valued at $7,846,000 after purchasing an additional 6,545 shares during the period.
Analyst Ratings Changes
Several equities analysts have weighed in on SOLV shares. Wall Street Zen cut Solventum from a "buy" rating to a "hold" rating in a research note on Sunday. Weiss Ratings restated a "hold (c)" rating on shares of Solventum in a report on Tuesday, January 27th. Zacks Research cut Solventum from a "strong-buy" rating to a "hold" rating in a research report on Monday, December 1st. BTIG Research reissued a "buy" rating and set a $100.00 price objective on shares of Solventum in a report on Friday, February 27th. Finally, KeyCorp raised their price objective on Solventum from $97.00 to $99.00 and gave the company an "overweight" rating in a research note on Friday, February 27th. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $93.70.
Check Out Our Latest Research Report on SOLV
Solventum Company Profile
(
Get Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
